心通医疗-B(02160.HK) 发盈警,预计2024年度亏损介乎3,000万至6,000万人民币,较2023年度减少87%-94%。主要因集团的经导管主动脉瓣膜植入术产品VitaFlow及VitaFlow Liberty和AnchorMan左心耳封堵器系统及其导引系统在内地的商业化有序推进,植入量持续增长;VitaFlow Liberty经导管主动脉瓣膜及可回收输送系统获得CE标志,并已在海外...
Source Link心通医疗-B(02160.HK) 发盈警,预计2024年度亏损介乎3,000万至6,000万人民币,较2023年度减少87%-94%。主要因集团的经导管主动脉瓣膜植入术产品VitaFlow及VitaFlow Liberty和AnchorMan左心耳封堵器系统及其导引系统在内地的商业化有序推进,植入量持续增长;VitaFlow Liberty经导管主动脉瓣膜及可回收输送系统获得CE标志,并已在海外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.